Distinguished in Primary Hyperoxaluria

Gema Ariceta

Barcelona, CT, ES 
Distinguished in Primary Hyperoxaluria
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Gema Ariceta practices in Barcelona, Spain. Ms. Ariceta is rated as a Distinguished expert by MediFind in the treatment of Primary Hyperoxaluria. Her top areas of expertise are Nephrocalcinosis, Atypical Hemolytic Uremic Syndrome (aHUS), D-Plus Hemolytic Uremic Syndrome, Kidney Transplant, and Nephrectomy.

Her clinical research consists of co-authoring 179 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles and participated in 2 clinical trials in the study of Primary Hyperoxaluria.

Gender
Female

Locations

Barcelona, CT 08035, Spain
Other Locations
Valles, VC, Spain
Bellaterra, CT, Spain
Barakaldo, PV, Spain
Bilbao, PV, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
Enrollment Status: Completed
Publish Date: December 10, 2021
Intervention Type: Other, Biological
Study Drug: Oxabact OC5 - Oxalobacter formigenes HC-1
Study Phase: Phase 3
An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02
An Open-label Single-arm Treatment Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact for Patients With Primary Hyperoxaluria Who Completed Study OC5-DB-02
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Biological
Study Drug: Oxabact OC5 - Oxalobacter formigenes Strain HC-1
Study Phase: Phase 3
View 2 Less Clinical Trials

178 Total Publications

The challenge of third and subsequents kidney transplantion in children.
The challenge of third and subsequents kidney transplantion in children.
Journal: Journal of pediatric urology
Published: June 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ariceta's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 18 Distinguished Conditions
View All 21 Advanced Conditions
View All 52 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile